TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07375758: A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy

Sponsor: Beijing Mabworks Biotech Co., Ltd. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07375758 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07375758 Rescue Dossier →